Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro

J Infect Dis. 2021 Oct 13;224(7):1109-1114. doi: 10.1093/infdis/jiab355.

Abstract

Whether monoclonal antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralize authentic SARS-CoV-2, including variant B.1.1.7 (alpha), but variants B.1.351 (beta) and P.2 (zeta) were resistant against bamlanivimab and partially resistant to casirivimab. Whether antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantshas been investigated using pseudoviruses. We show that authentic SARS-CoV-2 carrying E484K were resistant against bamlanivimab and less susceptible to casirivimab, convalescent and vaccine-elicited sera.

Keywords: SARS-CoV-2; bamlanivimab; casirivimab; convalescent; coronavirus; imdevimab; monoclonal antibodies; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Viral / immunology
  • COVID-19 / immunology
  • COVID-19 / virology*
  • Humans
  • Mutation, Missense
  • Neutralization Tests
  • SARS-CoV-2 / genetics*
  • SARS-CoV-2 / immunology*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Viral
  • imdevimab
  • bamlanivimab
  • casirivimab